Detection and quantification of small numbers of circulating tumour cells in peripheral blood using laser scanning cytometer (LSC®)

Clinical Chemistry and Laboratory Medicine

Volumn 39, Issue 9, 2001, Pages 811-817

  Pachmann, K ^a   Heiss P ^a   Demel, U ^a   Tilz, G ^a  

^a FRIEDRICH SCHILLER UNIVERSITY JENA   (Germany)

Author keywords

Laser scanning cytometry; Minimal residual disease; Solid tumours

Indexed keywords

FLUOROCHROME;

ANALYTIC METHOD; ARTICLE; BLOOD VOLUME; BREAST CANCER; CANCER CELL CULTURE; CELL COUNT; CONTROLLED STUDY; CYTOMETRY; HUMAN; HUMAN CELL; LASER MICROSCOPY; MODEL; PERIPHERAL CIRCULATION; PRIORITY JOURNAL; RELIABILITY; SCREENING; STAINING; TUMOR CELL;

BREAST NEOPLASMS; CELL SEPARATION; FLOW CYTOMETRY; FLUORESCENCE; HUMANS; IMAGE CYTOMETRY; MAGNETICS; MICROSCOPY, CONFOCAL; NEOPLASM CIRCULATING CELLS; SENSITIVITY AND SPECIFICITY;

EID: 17944363389     PISSN: 14346621     EISSN: None     Source Type: Journal    
DOI: 10.1515/CCLM.2001.134     Document Type: Article

References (26)

1. Minimal residual disease in solid tumour malignancies: A review
2. Role of tumour cells contaminating the graft in breast cancer recurrence after high dose chemotherapy
3. Detection of rare MCF-7 breast carcinoma cells from mixtures of human peripheral leucocytes by magnetic deposition analysis
4. Minimal residual disease in solid cancer: The diagnostic and therapeutic opportunity for monoclonal antibodies
5. Detection of minimal disease in patients with solid tumours
6. Polymerase chain reaction in the detection of micrometastases and circulating tumour cells
7. Molecular detection of minimal residual disease in colorectal and breast cancer
8. Identification of mammary metastatic cells in the bone marrow as a marker of a minimal residual disease and of their proliferative index as a factor of prognosis - An immunocytologic study with monoclonal antibodies
9. Detection of immunocytochemically stained rare events using image analysis
10. Flow cytometry - Principles feasibility in transfusion medicine. Enumeration of epithelial derived tumour cells in peripheral blood
11. Comparison of molecular cytokeratin 19 reverse transcriptase polymerase chain reaction (CK19 RT-PCR) and immunocytochemical detection of micrometastatic brest cancer cells in hematopoietic harvests
12. Detection of tumour cells in the bone marrow of stage IV breast cancer patients receiving high-dose chemotherapy: The role of induction therapy
13. Occult tumour contamination of hematopoietic stem cell products does not affect clinical outcome of autologous transplantation in patients with metastatic breast cancer
14. Detection of minimal residual disease in hematopoietic tissues
15. A seminested RT-PCR assay for HER2/neu: Initial validation of a new method for the detection of disseminated breast cancer cells
16. High sensitivity detection of minimal residual breast carcinoma using the polymerase chain reaction and primers for cytokeratin 19
17. Tumour antigen heterogeneity of disseminated breast cancer cells: Implications for immunotherapy of minimal residual disease
18. Detection and characterization of residual disease in breast cancer
19. -7
20. Immunomagnetic techniques for the enrichment and detection of isolated breast carcinoma cells in bone marrow and peripheral blood
21. Specificity of reverse transcriptase reaction assays designed for the detection of circulating cancer cells is influenced by cytokines in vivo and in vitro
22. Laser scanning cytometry: A new instrumentation with many applications
23. Epithelial glycoprotein-2 expression is subject to regulatory processes in epithelial-mesenchymal transitions during metastases: An investigation of human cancers transplanted into severe combined immunodeficient mice
24. Immunocytochemical detection of breast cancer cells in marrow and peripheral blood of patients undergoing high dose chemotherapy with autologous stem cell support
25. In situ amplification of rearranged gene sequences in individual cells for tracing clonal cells in smears from blood and bone marrow
26. Mobilization of tumour cells and hematopoietic progenitor cells into peripheral blood of patients with solid tumours